220605-36-7Relevant academic research and scientific papers
Thiazine amide derivative thereof in the preparation of medicaments for preventing neurodegenerative diseases, the use of the
-
Paragraph 0021; 0033-0034, (2017/02/23)
The invention relates to a compound shown as the formula I, pharmaceutically acceptable salts of the compound, and/ or solvates and/ or hydrates of the compound. The invention also relates to a preparation method of the compound, a medicinal composition c
THIAZINE AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
-
Paragraph 0046, (2015/07/15)
The present invention relates to a thiazine amide derivative and a pharmaceutical use thereof, and particularly to a compound of formula I (in the formula, variables are as described in the specification), a pharmaceutically acceptable salt, solvate or hy
Thiazine Amide Derivative and Pharmaceutical Composition and Use Thereof
-
Paragraph 0065, (2015/07/27)
The present invention relates to a thiazine amide derivative and a pharmaceutical use thereof, and particularly to a compound of formula I (in the formula, variables are as described in the specification), a pharmaceutically acceptable salt, solvate or hy
STEROID SPARING AGENTS AND METHODS OF USING SAME
-
Page/Page column 383; 399; 401, (2010/02/14)
This invention relates generally to the use of a steroid sparing agent for the preparation of a medicament for the treatment of inflammatory bowel diseases (IBD), asthma, multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.
Substituted 6?membered n?heterocyclic compounds and their uses as neurological regulator
-
Page/Page column 6, (2008/06/13)
This invention relates to substituted 6-membered N-Herterocyclic neurotrophic compounds of formula (I) or pharmaceutically acceptable salts or hydrates thereof, wherein R1, R2, X, Y, and Z are as defined in the description; their pre
